Safety, Tolerability, and Effect of TMC207 and Efavirenz in Healthy Volunteers
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
Common treatments for tuberculosis (TB) can interfere with certain antiretroviral (ARV)
medications used to treat HIV. People whose immune systems are weakened by HIV infection are
susceptible to TB, so it is important to find treatments for both that can be given in
combination. This study will test the safety of combining a new medication for TB with an
already approved HIV medication in healthy adults.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)